Evaluations
Evaluations
Access all IFFIm evaluations
IFFIm evaluation: The World Bank response
01 July 2011
The World Bank has reviewed an evaluation report of the International Finance Facility for Immunisation (IFFIm) prepared by HLSP and dated June 2011. The World Bank provides services to IFFIm under the Treasury Management Agreement and this report substantially reviews those activities in the context of IFFIm’s overall performance as a financing vehicle.
- Author(s): The World Bank
IFFIm evaluation: key messages
01 July 2011
The International Financing Facility for Immunisation (IFFIm) concept is proven. IFFIm has allowed donor countries to make binding long-term commitments and convert these future cash flows into immediately available funds through the financial markets at a cost very close to that achieved by the World Bank.
- Author(s): HLSP
IFFIm evaluation: executive summary
01 July 2011
This evaluation was commissioned by the GAVI Secretariat, on behalf of the IFFIm Board, to assess the extent to which the IFFIm has been an effective financing mechanism to raise money for immunisation and health systems in Gavi eligible countries.
- Author(s): HLSP
IFFIm evaluation: IFFIm donor response
01 July 2011
Donors feel that the report presents valuable information about the goal effectiveness, costs effectiveness, and impacts in terms of lives saved by IFFIm. The evaluation shows, while highlighting constraints (size), lost opportunities (frontloading too early) and potential challenges (sustainability), that IFFIm has so far achieved impacts beyond those specifically targeted for immunisation.
- Author(s): IFFIm donors
IFFIm evaluation: IFFIm Board response
01 July 2011
This paper provides a response to the IFFIm Evaluation by the IFFIm Board of Directors.
- Author(s): IFFIm Board of Directors
IFFIm evaluation: GAVI Secretariat response
28 June 2011
GAVI Secretariat response to IFFIm evaluation which assessed both IFFIm’s efficacy as a financing mechanism, as well as the extent to which IFFIm has contributed to enhancing GAVI’s impact on immunisation and health.
- Author(s): GAVI Secretariat
IFFIm evaluation: full report
21 June 2011
The IFFIm evaluation assesses the extent to which IFFIm is an effective and efficient instrument to attract long-term, predictable donor funds and to frontload money to finance GAVI Alliance support for immunisation and health systems.
- Author(s): HLSP
IFFIm evaluation: annexes
20 April 2011
Annexes of the IFFIm evaluation.
- Author(s): HLSP
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.